<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-35934" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperhomocysteinemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Son</surname>
            <given-names>Phillip</given-names>
          </name>
          <aff>PBCGME Family Medicine Residency</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lewis</surname>
            <given-names>Lindsay</given-names>
          </name>
          <aff>St Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Phillip Son declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lindsay Lewis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-35934.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperhomocysteinemia refers to the condition where there is greater than 15 micromol/L of homocysteine in the blood. This condition is present in a wide range of diseases, and in many cases, it is an independent risk factor for more serious medical conditions. However, the evaluation and management of this condition remain controversial. This activity reviews the evaluation and management of hyperhomocysteinemia and highlights the role of the interprofessional team in managing this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the indications for obtaining a homocysteine level.</p></list-item><list-item><p>Summarize who should receive treatment for hyperhomocysteinemia.</p></list-item><list-item><p>Identify patients who would have elevated homocysteine levels.</p></list-item><list-item><p>Explain the importance of the interprofessional team to enhance care coordination for patients who have hyperhomocysteinemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35934&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35934">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-35934.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Homocysteine is an amino acid not supplied by the diet that can be converted into cysteine or recycled into methionine, an essential amino acid, with the aid of specific B vitamins. Homocysteine levels vary between men and women, with a normal range typically between 5 to 15 micromol/L. Hyperhomocysteinemia is when levels exceed 15 micromol/L.&#x000a0;<xref ref-type="bibr" rid="article-35934.r1">[1]</xref></p>
        <p>When homocysteine levels are greater than normal limits, it signifies a disruption in the metabolism of homocysteine.<xref ref-type="bibr" rid="article-35934.r1">[1]</xref> Elevated levels of homocysteine have been associated with increased cardiovascular, cerebrovascular, and thromboembolic diseases.<xref ref-type="bibr" rid="article-35934.r2">[2]</xref><xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r4">[4]</xref> While there are clear associations between homocysteine and cerebrovascular disease, the evaluation and treatment remain controversial as studies have shown conflicting results in its effect in lowering risks for cardiovascular and cerebrovascular disease.<xref ref-type="bibr" rid="article-35934.r4">[4]</xref><xref ref-type="bibr" rid="article-35934.r5">[5]</xref><xref ref-type="bibr" rid="article-35934.r6">[6]</xref>&#x000a0;There has been clear evidence that lowering homocysteine levels decreases cardiovascular risks in patients with homocystinuria, a rare autosomal recessive disorder, which can lead to atherosclerotic disease at a young age.<xref ref-type="bibr" rid="article-35934.r7">[7]</xref><xref ref-type="bibr" rid="article-35934.r8">[8]</xref> Also, some studies have shown that lowering homocysteine levels can be beneficial in slowing the acceleration of brain atrophy.<xref ref-type="bibr" rid="article-35934.r9">[9]</xref>&#x000a0;On the other hand, a meta-analysis by the American Heart Association showed that&#x000a0;homocysteine-lowering therapies did not significantly affect averting stroke&#x000a0;<xref ref-type="bibr" rid="article-35934.r4">[4]</xref>&#x000a0;and have a non-significant impact on coronary heart disease.<xref ref-type="bibr" rid="article-35934.r5">[5]</xref></p>
        <p>Homocysteine levels are generally categorized into three groups: moderate (16&#x000a0;to 30 micromol/L), intermediate (31&#x000a0;to 100 micromol/L), and severe (over 100 micromol/L).<xref ref-type="bibr" rid="article-35934.r10">[10]</xref></p>
      </sec>
      <sec id="article-35934.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Homocysteine is converted to cysteine and methionine by a combination of B vitamins (B12, B6, and folate) and enzymes (Methylene Tetrahydrofolate Reductase: MTHFR). Specifically, homocysteine is converted to methionine by a process known as remethylation with the help of vitamin B12.&#x000a0; Methionine can subsequently be broken down to S-adenosyl-methionine to be regenerated to homocysteine. In a reaction called transsulfuration, homocysteine is converted to cysteine catalyzed by pyridoxal-5&#x02019;-phosphate (PLP) and cystathionine B-synthase. Elevations in homocysteine suggest disruptions in one of the components of this reaction.<xref ref-type="bibr" rid="article-35934.r1">[1]</xref><xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r11">[11]</xref>&#x000a0;While there are numerous causes for this condition, one of the most common causes of hyperhomocysteinemia is the inadequate enzyme activity of MTHFR due to genetic defects.<xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r12">[12]</xref>&#x000a0;Because vitamins play such a crucial role in the biochemistry of homocysteine, any causes of vitamin B12, B6, and folate deficiency (i.e., alcohol use, proton pump inhibitors) can theoretically cause elevated homocysteine.<xref ref-type="bibr" rid="article-35934.r13">[13]</xref><xref ref-type="bibr" rid="article-35934.r14">[14]</xref>&#x000a0;Other diseases that correlate with elevated homocysteine levels include hip fracture, cognitive decline, osteoporosis, chronic kidney disease,&#x000a0;hypothyroidism, Alzheimer disease, and schizophrenia.<xref ref-type="bibr" rid="article-35934.r2">[2]</xref><xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r9">[9]</xref><xref ref-type="bibr" rid="article-35934.r15">[15]</xref><xref ref-type="bibr" rid="article-35934.r16">[16]</xref><xref ref-type="bibr" rid="article-35934.r17">[17]</xref><xref ref-type="bibr" rid="article-35934.r18">[18]</xref></p>
      </sec>
      <sec id="article-35934.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The estimated prevalence of mild hyperhomocysteinemia is 5 to 7% in the general population.&#x000a0;Several studies have shown that it is an independent risk factor for thrombotic disorders (i.e., deep vein thrombosis).<xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r4">[4]</xref>&#x000a0;It has even been reported that lowering a patient's homocysteine levels by 25% decreases stroke risk by 19%.<xref ref-type="bibr" rid="article-35934.r4">[4]</xref></p>
      </sec>
      <sec id="article-35934.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Elevated levels of homocysteine can increase the risk of atherosclerosis&#x000a0;by causing endothelial layer injury, promoting inflammation,&#x000a0;and increasing oxidative stress.<xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r4">[4]</xref>&#x000a0;However, the exact mechanism is still unknown, and more research needs to be done&#x000a0;to identify the pathophysiology. In relation to brain atrophy and cognitive decline, the correlation with elevated homocysteine levels is unclear but has been speculated to be a finding related to vitamin deficiencies. However, in studies, there was no relationship between baseline levels of tHcy and the rate of atrophy in people who were being treated for hyperhomocysteinemia, which suggests that homocysteine is a direct cause of brain atrophy.<xref ref-type="bibr" rid="article-35934.r9">[9]</xref></p>
        <p>There are multiple pathways to which elevated homocysteine levels can lead to schizophrenia. Elevated total homocysteine levels in the third trimester of pregnancy may cause subtle damage to the vasculature of the placenta, which can limit oxygen to the fetus and may have a direct effect on the brain structure of the fetus and thus increase the risk of developing schizophrenia.<xref ref-type="bibr" rid="article-35934.r19">[19]</xref><xref ref-type="bibr" rid="article-35934.r20">[20]</xref>&#x000a0;Homocysteine may also play a role in schizophrenia via effects on the NMDA receptor by initiating oxidative stress, which leads to vascular inflammation.<xref ref-type="bibr" rid="article-35934.r21">[21]</xref></p>
        <p>The pathogenesis of hip fracture and elevated homocysteine levels is speculated to be due to homocysteine interference in collagen cross-linking, which alters the bone matrix and increases the fragility of the bones.<xref ref-type="bibr" rid="article-35934.r18">[18]</xref></p>
      </sec>
      <sec id="article-35934.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The presentation of hyperhomocysteinemia varies due to the underlying cause and, in some cases, is asymptomatic. Patients presenting with any cardiovascular and cerebrovascular disorders can have elevated homocysteine levels and can be asymptomatic.<xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r4">[4]</xref><xref ref-type="bibr" rid="article-35934.r5">[5]</xref>&#x000a0;Also, it is possible that elevated homocysteine levels can be found in those who are vitamin B12, B6, and folate deficiency. In these patients, symptoms could range from fatigue, numbness/tingling to weight loss, and dementia.<xref ref-type="bibr" rid="article-35934.r22">[22]</xref>&#x000a0;Some other symptoms/diseases that can present in hyperhomocysteinemia include hip fracture, cognitive decline, osteoporosis, chronic kidney disease, hypothyroidism, Alzheimer disease, and schizophrenia.<xref ref-type="bibr" rid="article-35934.r2">[2]</xref><xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r9">[9]</xref><xref ref-type="bibr" rid="article-35934.r15">[15]</xref><xref ref-type="bibr" rid="article-35934.r16">[16]</xref><xref ref-type="bibr" rid="article-35934.r17">[17]</xref><xref ref-type="bibr" rid="article-35934.r18">[18]</xref></p>
      </sec>
      <sec id="article-35934.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The initial evaluation of hyperhomocysteinemia includes a thorough history and physical exam to look for any signs and symptoms of homocystinuria, a rare but deadly disease.<xref ref-type="bibr" rid="article-35934.r7">[7]</xref>&#x000a0;It would present as an ectopic lens and developmental delay in children, whereas in adults, it would manifest as vascular disease. Other signs and symptoms include a family history of homocystinuria, osteoporosis, glaucoma, and retinal detachment, especially in children and young adults.<xref ref-type="bibr" rid="article-35934.r10">[10]</xref>&#x000a0;In these patients, homocysteine levels should be obtained.&#x000a0;</p>
        <p>In patients who do not have signs and symptoms of homocystinuria, the decision to measure homocysteine levels and pursue treatment remains controversial. According to the American Heart Association (AHA), homocysteine levels do not predict cardiovascular disease development. Lowering homocysteine levels does not improve clinical outcomes, nor does it prevent future cardiovascular and thromboembolic diseases with treatment.<xref ref-type="bibr" rid="article-35934.r4">[4]</xref><xref ref-type="bibr" rid="article-35934.r5">[5]</xref><xref ref-type="bibr" rid="article-35934.r7">[7]</xref><xref ref-type="bibr" rid="article-35934.r6">[6]</xref></p>
        <p>On the other hand, some studies showed that lowering the homocysteine level was beneficial. One study was able to show that lowering hyperhomocysteinemia through folic acid supplementation would reduce carotid atherosclerosis progression.<xref ref-type="bibr" rid="article-35934.r4">[4]</xref>&#x000a0;In addition, a randomized control study noted that patients who have mild cognitive impairment and received 0.8 mg of folic acid, 0.5 mg of vitamin B12, and 20 mg of B6 for 24 months were noted to have decreased brain atrophy and a slowing of cognitive decline. These patients also had no safety issues while being on this homocysteine-lowering treatment.<xref ref-type="bibr" rid="article-35934.r9">[9]</xref>&#x000a0;Therefore, in these patients, a discussion between the clinician and patient is warranted on the risks and benefits of obtaining a homocysteine level.</p>
      </sec>
      <sec id="article-35934.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Several studies have tried to demonstrate the efficacy of vitamin supplementation to reduce cardiovascular and thromboembolic risk. The American Heart Association explained that folic acid supplementation (0.2 to 15 mg/d) could lower homocysteine levels. However, randomized control trials&#x000a0;have been controversial in showing cardiovascular risk reduction with folic acid supplementation unless a patient has homocystinuria.<xref ref-type="bibr" rid="article-35934.r5">[5]</xref><xref ref-type="bibr" rid="article-35934.r7">[7]</xref></p>
        <p>In patients with homocystinuria with severe hyperhomocysteinemia, homocysteine-lowering treatments with pyridoxine, folic acid, and hydroxocobalamin did reduce cardiovascular risk.<xref ref-type="bibr" rid="article-35934.r8">[8]</xref>&#x000a0;</p>
        <p>In patients who have hyperhomocysteinemia without homocystinuria, treatment remains controversial. Randomized control trials have not been able to show a reduction in cardiovascular risk for those who lower homocysteine levels using homocysteine-lowering therapies.<xref ref-type="bibr" rid="article-35934.r7">[7]</xref><xref ref-type="bibr" rid="article-35934.r6">[6]</xref><xref ref-type="bibr" rid="article-35934.r23">[23]</xref>&#x000a0;However, studies have also shown that it can potentially reduce carotid atherosclerosis progression, have mild primary stroke prevention benefits, and delay brain atrophy in patients with mild cognitive impairment in patients who have been treated with homocysteine-lowering medications.<xref ref-type="bibr" rid="article-35934.r4">[4]</xref><xref ref-type="bibr" rid="article-35934.r9">[9]</xref>&#x000a0;Therefore, the clinician must have a detailed discussion of the risks and benefits of obtaining and treating an elevated homocysteine level. Compared to the risks, placing a patient on a vitamin B supplement readily over-the-counter seems to have more benefits.</p>
      </sec>
      <sec id="article-35934.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for hyperhomocysteinemia, especially in homocystinuria (i.e., these patients would have marfanoid habitus and ectopic lens), includes Marfan syndrome and sulfite oxidate deficiency syndrome. Differentiating among these conditions is crucial as studies have pointed out their similarities. Obtaining a homocysteine level will distinguish these diseases from homocystinuria.<xref ref-type="bibr" rid="article-35934.r24">[24]</xref>&#x000a0;Other conditions where elevated homocysteine levels would be present are hip fracture, cognitive decline, osteoporosis, chronic kidney disease,&#x000a0;hypothyroidism, Alzheimer disease, and schizophrenia.<xref ref-type="bibr" rid="article-35934.r2">[2]</xref><xref ref-type="bibr" rid="article-35934.r3">[3]</xref><xref ref-type="bibr" rid="article-35934.r9">[9]</xref><xref ref-type="bibr" rid="article-35934.r15">[15]</xref><xref ref-type="bibr" rid="article-35934.r16">[16]</xref><xref ref-type="bibr" rid="article-35934.r17">[17]</xref><xref ref-type="bibr" rid="article-35934.r18">[18]</xref></p>
      </sec>
      <sec id="article-35934.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of severe hyperhomocysteinemia in the setting of homocystinuria is poor if it is left untreated. For patients with hyperhomocysteinemia without homocystinuria, the prognosis is difficult to assess as there is not enough research. However, theoretically, there is an increased risk for osteoporosis, schizophrenia, and brain atrophy in specific populations that can increase the morbidity of these patients. Therefore, further research is needed to determine a patient's prognosis when diagnosed with elevated homocysteine.<xref ref-type="bibr" rid="article-35934.r7">[7]</xref><xref ref-type="bibr" rid="article-35934.r9">[9]</xref><xref ref-type="bibr" rid="article-35934.r10">[10]</xref><xref ref-type="bibr" rid="article-35934.r18">[18]</xref><xref ref-type="bibr" rid="article-35934.r19">[19]</xref></p>
      </sec>
      <sec id="article-35934.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Potential complications of hyperhomocysteinemia in the setting of homocystinuria include retinal detachment, glaucoma, and vascular disease as children or young adults.<xref ref-type="bibr" rid="article-35934.r10">[10]</xref>&#x000a0;For patients who have hyperhomocysteinemia without homocystinuria, there is an increased risk for atherosclerotic events.<xref ref-type="bibr" rid="article-35934.r7">[7]</xref><xref ref-type="bibr" rid="article-35934.r8">[8]</xref>&#x000a0;Also, there is an increased risk for hip fractures and brain atrophy for specific populations, as well as an increased risk of developing schizophrenia.<xref ref-type="bibr" rid="article-35934.r9">[9]</xref><xref ref-type="bibr" rid="article-35934.r18">[18]</xref><xref ref-type="bibr" rid="article-35934.r19">[19]</xref></p>
      </sec>
      <sec id="article-35934.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Especially for the primary care physician, we believe that it is reasonable to discuss the evaluation of hyperhomocysteinemia, including the controversial nature of the treatment. The first step would be to discuss the patient&#x02019;s intake of foods with folic acid, vitamin B6, and B12 to see if the patient is meeting the recommended dietary amount for these vitamins. If they are not meeting these requirements, recommendations can be made to increase foods rich in these vitamins, such as fruits and vegetables, as a portion of the general population does not meet the Recommended Dietary Allowance (RDA) for these nutrients.<xref ref-type="bibr" rid="article-35934.r7">[7]</xref>&#x000a0;In addition, education would have to be on a case-by-case basis based on the patient&#x02019;s disease. For patients with signs and symptoms of homocystinuria or mild cognitive impairment, the benefits of vitamin B supplementation outweigh the risks; therefore, supplementation is recommended. There is not enough evidence to support the use of homocysteine-lowering treatments&#x000a0;across the board for all other patients.<xref ref-type="bibr" rid="article-35934.r4">[4]</xref><xref ref-type="bibr" rid="article-35934.r5">[5]</xref><xref ref-type="bibr" rid="article-35934.r7">[7]</xref><xref ref-type="bibr" rid="article-35934.r9">[9]</xref></p>
      </sec>
      <sec id="article-35934.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>At this time,&#x000a0;it is recommended that only those with signs and symptoms of homocystinuria and mild cognitive impairment are evaluated and treated for hyperhomocysteinemia.<xref ref-type="bibr" rid="article-35934.r7">[7]</xref><xref ref-type="bibr" rid="article-35934.r9">[9]</xref>&#x000a0;[Level 2] This subset of the patient population will most likely benefit from treatment, as demonstrated by randomized control trials. For all other patients,&#x000a0;physicians, and other healthcare professionals, operating as a cohesive interprofessional team need to have a discussion with their patients about the risks and benefits of obtaining a homocysteine level. Pharmacists should assist patients in selecting supplements, recommending appropriate dosing and administration, and checking for drug interactions. Dieticians and nutritionists educate patients. Specialty trained nurses in cardiology also provide guidance and arrange referrals and follow up. All these healthcare providers need to contact the clinician if they encounter any issues within their particular discipline. This type of interprofessional collaboration can result in better outcomes for patients with hyperhomocysteinemia. [Level 5]</p>
      </sec>
      <sec id="article-35934.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35934&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35934">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/hyperhomocysteinemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=35934">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/35934/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=35934">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-35934.s15">
        <title>References</title>
        <ref id="article-35934.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veeranki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gandhapudi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Tyagi</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Interactions of hyperhomocysteinemia and T cell immunity in causation of hypertension.</article-title>
            <source>Can J Physiol Pharmacol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>239</fpage>
            <page-range>239-246</page-range>
            <pub-id pub-id-type="pmid">27398734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bostom</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Levey</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hunsicker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Selhub</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacques</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gravens-Mueller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>House</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kew</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pacheco-Silva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pesavento</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pirsch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>Apr</month>
            <day>26</day>
            <volume>123</volume>
            <issue>16</issue>
            <fpage>1763</fpage>
            <page-range>1763-70</page-range>
            <pub-id pub-id-type="pmid">21482964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Clinical Implications of Methylenetetrahydrofolate Reductase Mutations and Plasma Homocysteine Levels in Patients with Thromboembolic Occlusion.</article-title>
            <source>Vasc Specialist Int</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>113</fpage>
            <page-range>113-9</page-range>
            <pub-id pub-id-type="pmid">26217629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Saver</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis.</article-title>
            <source>Stroke</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>1205</fpage>
            <page-range>1205-12</page-range>
            <pub-id pub-id-type="pmid">20413740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Muka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Troup</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>FB</given-names>
              </name>
            </person-group>
            <article-title>Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2016</year>
            <month>Aug</month>
            <day>15</day>
            <volume>5</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">27528407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;-Carvajal</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sol&#x000e0;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lathyris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dayer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine-lowering interventions for preventing cardiovascular events.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Aug</month>
            <day>17</day>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>CD006612</fpage>
            <pub-id pub-id-type="pmid">28816346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malinow</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bostom</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.</article-title>
            <source>Circulation</source>
            <year>1999</year>
            <month>Jan</month>
            <day>5-12</day>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>178</fpage>
            <page-range>178-82</page-range>
            <pub-id pub-id-type="pmid">9884399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilcken</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Wilcken</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The natural history of vascular disease in homocystinuria and the effects of treatment.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-300</page-range>
            <pub-id pub-id-type="pmid">9211201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>de Jager</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Whitbread</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agacinski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oulhaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Refsum</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.</article-title>
            <source>PLoS One</source>
            <year>2010</year>
            <month>Sep</month>
            <day>08</day>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>e12244</fpage>
            <pub-id pub-id-type="pmid">20838622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ko&#x0017e;ich</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Santra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Andria</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ben-Omran</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Chakrapani</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Crushell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hochuli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huemer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Maillot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mayne</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>McNulty</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ogier</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pavl&#x000ed;kov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Almeida</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Terry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blom</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-74</page-range>
            <pub-id pub-id-type="pmid">27778219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bostom</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Lathrop</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes.</article-title>
            <source>Kidney Int</source>
            <year>1997</year>
            <month>Jul</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-20</page-range>
            <pub-id pub-id-type="pmid">9211341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antoniades</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shirodaria</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leeson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baarholm</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Van-Assche</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cunnington</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pillai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ratnatunga</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tousoulis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stefanadis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Refsum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Channon</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>MTHFR 677 C&#x0003e;T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>May</month>
            <day>12</day>
            <volume>119</volume>
            <issue>18</issue>
            <fpage>2507</fpage>
            <page-range>2507-15</page-range>
            <pub-id pub-id-type="pmid">19398669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cylwik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chrostek</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Disturbances of folic acid and homocysteine metabolism in alcohol abuse].</article-title>
            <source>Pol Merkur Lekarski</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>178</issue>
            <fpage>295</fpage>
            <page-range>295-9</page-range>
            <pub-id pub-id-type="pmid">21595178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirschowitz</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Worthington</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mohnen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2008</year>
            <month>Jun</month>
            <day>01</day>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>1110</fpage>
            <page-range>1110-21</page-range>
            <pub-id pub-id-type="pmid">18315582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cianciolo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Pascalis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Lullo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zannini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>La Manna</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First?</article-title>
            <source>Cardiorenal Med</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>255</fpage>
            <page-range>255-266</page-range>
            <pub-id pub-id-type="pmid">29118764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smach</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Golmard</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Charfeddine</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lammouchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ben Othman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dridi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bennamou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Limem</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer's disease or dementia: a case control study.</article-title>
            <source>Eur Neurol</source>
            <year>2011</year>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>270</fpage>
            <page-range>270-8</page-range>
            <pub-id pub-id-type="pmid">21474939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dietrich-Muszalska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malinowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>G&#x00142;owacki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wachowicz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rabe-Jab&#x00142;o&#x00144;ska</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients.</article-title>
            <source>Neurochem Res</source>
            <year>2012</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>1057</fpage>
            <page-range>1057-62</page-range>
            <pub-id pub-id-type="pmid">22270909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leboff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Narweker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>LaCroix</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cauley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kooperberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine levels and risk of hip fracture in postmenopausal women.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>1207</fpage>
            <page-range>1207-13</page-range>
            <pub-id pub-id-type="pmid">19174498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Bottiglieri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Quesenberry</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bresnahan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Susser</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Elevated prenatal homocysteine levels as a risk factor for schizophrenia.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-9</page-range>
            <pub-id pub-id-type="pmid">17199052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Numata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tajima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nishi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Imoto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ohmori</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis.</article-title>
            <source>BMC Med Genet</source>
            <year>2015</year>
            <month>Jul</month>
            <day>26</day>
            <volume>16</volume>
            <fpage>54</fpage>
            <pub-id pub-id-type="pmid">26208850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moustafa</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Hewedi</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Eissa</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Frydecka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Misiak</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine levels in schizophrenia and affective disorders-focus on cognition.</article-title>
            <source>Front Behav Neurosci</source>
            <year>2014</year>
            <volume>8</volume>
            <fpage>343</fpage>
            <pub-id pub-id-type="pmid">25339876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langan</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Goodbred</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B12 Deficiency: Recognition and Management.</article-title>
            <source>Am Fam Physician</source>
            <year>2017</year>
            <month>Sep</month>
            <day>15</day>
            <volume>96</volume>
            <issue>6</issue>
            <fpage>384</fpage>
            <page-range>384-389</page-range>
            <pub-id pub-id-type="pmid">28925645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hankey</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine and vascular disease.</article-title>
            <source>Lancet</source>
            <year>1999</year>
            <month>Jul</month>
            <day>31</day>
            <volume>354</volume>
            <issue>9176</issue>
            <fpage>407</fpage>
            <page-range>407-13</page-range>
            <pub-id pub-id-type="pmid">10437885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sacharow</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Picker</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <chapter-title>Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2004</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">20301697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35934.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selhub</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine metabolism.</article-title>
            <source>Annu Rev Nutr</source>
            <year>1999</year>
            <volume>19</volume>
            <fpage>217</fpage>
            <page-range>217-46</page-range>
            <pub-id pub-id-type="pmid">10448523</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
